Top Markets
Coin of the day
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Classifica tra le azioni #6138
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Prezzo delle azioni
$154.04
Capitalizzazione di mercato
$2.21B
Variazione (1 giorno)
-0.19%
Variazione (1 anno)
172.88%
Paese
US
Scambia Palvella Therapeutics, Inc. (PVLA)

Categoria

EPS per Palvella Therapeutics, Inc. (PVLA)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Palvella Therapeutics, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Palvella Therapeutics, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH